Scholar Rock (SRRK)
(Real Time Quote from BATS)
$8.78 USD
0.00 (0.00%)
Updated Sep 5, 2024 10:28 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Scholar Rock Holding Corporation (SRRK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$26.88 | $34.00 | $20.00 | 206.15% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Scholar Rock Holding Corporation comes to $26.88. The forecasts range from a low of $20.00 to a high of $34.00. The average price target represents an increase of 206.15% from the last closing price of $8.78.
Analyst Price Targets (8 )
Broker Rating
Scholar Rock Holding Corporation currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, nine are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SRRK.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/9/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
8/9/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/8/2024 | Raymond James | Gary Nachman | Strong Buy | Strong Buy |
8/8/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
6/27/2024 | Piper Sandler | Allison M Bratzel | Strong Buy | Strong Buy |
6/25/2024 | H.C. Wainwright & Co. | Andres Y Maldonado | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 9 |
Average Target Price | $26.88 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -0.62 |